[go: up one dir, main page]

EP4633390A1 - Produit alimentaire destiné à être utilisé dans la prévention et le traitement de xylostomiases induites par l'alcool - Google Patents

Produit alimentaire destiné à être utilisé dans la prévention et le traitement de xylostomiases induites par l'alcool

Info

Publication number
EP4633390A1
EP4633390A1 EP23841545.9A EP23841545A EP4633390A1 EP 4633390 A1 EP4633390 A1 EP 4633390A1 EP 23841545 A EP23841545 A EP 23841545A EP 4633390 A1 EP4633390 A1 EP 4633390A1
Authority
EP
European Patent Office
Prior art keywords
alcohol
product
patent application
per
silymarin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP23841545.9A
Other languages
German (de)
English (en)
Inventor
Mirco GOMIERO
Raffaele PAPA
Roberto Brusadin
Paolo BRUSADIN
Daniele SABBADIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alchimia Innovazione Srl
Original Assignee
Alchimia Innovazione Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alchimia Innovazione Srl filed Critical Alchimia Innovazione Srl
Publication of EP4633390A1 publication Critical patent/EP4633390A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Definitions

  • This patent application pertains to a food composition capable of suppressing the negative ef fects of the blood alcohol level , lowering the alcohol level in the blood by promoting its metabol ism .
  • the found subj ect of thi s patent application is applicable in the field of producing food compositions , particularly liquid food compositions , speci fically in the sector of producing liquid food compositions as dietary supplements for use in preventing and treating the afteref fects of excessive alcohol consumption .
  • ethanol is metaboli zed to acetaldehyde and from acetaldehyde to acetate through an enzyme - alcohol dehydrogenase (ALDH) - predominantly found in hepatic mitochondria .
  • Acetate is released into the bloodstream from the liver and then trans ferred to tissues .
  • ROS reactive oxygen species
  • Vitamin E deficiency increases lipid peroxidation (LPO) , leading to increased production of malondialdehyde (MDA) [9] .
  • Vitamin A deficiency contributes to lysosomal damage, while decreased glutathione content leads to mitochondrial dysfunction and increased susceptibility of cells to apoptosis State of the art
  • the physiological time for reducing the alcohol level in the human body is dependent on the alcohol concentration itself. For instance, 12 grams of alcohol are metabolized within a variable timeframe, ranging between two to three hours, based on factors such as the individual's weight, gender, dietary conditions (full or empty stomach) , and liver condition.
  • a first set of products consists of plant extracts containing polyphenols, purportedly aiming to increase the activity of antioxidant enzymes like superoxide dismutase and reduce c i r cul a L mg MJJA.
  • preparations are known in the state of the art containing a mixture of silybin, silicristin, and silidianin in ratios of 3:1:1, known as Silymarin, supplemented with other components that appear to have an immediate detoxifying action, reducing the alcohol content in the blood in the short term.
  • Creatine promotes ATP formation, helping to counteract the feeling of fatigue caused by alcohol intoxication.
  • Silybum marianum extract works on the digestive function with a purifying and antioxidant action. Specifically, the silymarin— a complex of bioflavonoids within the extract- acts as a defense against various intoxicating substances, including alcohol.
  • Patent US2019298684 describes a composition to reduce or mitigate the negative effects resulting from the consumption of alcoholic beverages.
  • This composition includes dihydromyricetin C15H12O, a source of free-form silymarin, and pyrroloquinoi ine quinone.
  • the free-form silymarin despite its known positive effects, appears to be inefficiently assimilated by the body, resulting in a loss of effectiveness of the composition.
  • the purpose of the present patent application is to create a food composition for use in preventing and treating the aftereffects of intoxication, where said composition acts on the alcohol concentration in the blood.
  • the further purpose of the invention described in this patent application is to create a discovery that can decrease the concentration of alcohol in the blood within a timeframe shorter than the physiologically necessary time, which, in an average individual, typically takes about 2-3 hours.
  • Another purpose of the invention subject to this patent application is to create a dietary composition for the prevention and treatment of hangover symptoms, said composition aiming to have effects in reducing oxidative stress.
  • the subject matter of this patent application is a food product comprising a complex of Silybum Marianum and phospholipids, hereinafter referred to as 'silymarin phytosome, ' sodium salt of pyrroloquinoline quinone, and 3, 5, 7-Trihydroxy-2 (3,4,5 — trihydroxyphenyl) -4-chromenone, hereinafter referred to as 'myricetin.
  • This product is preferably, but not exclusively, in an aqueous solution.
  • the invention subject to this patent application consists of a food preparation, referred to as such, comprising flavonoids and peptides in an aqueous solution.
  • the food preparation subject to this patent application includes:
  • Flavonoids silymarin phytosome, myricetin,
  • Peptides sodium salt of pyrroloquinoline; said preparation being able to act on alcohol levels and oxidative stress markers caused by alcohol intake.
  • the invention subject to this patent application consists of a liquid food preparation.
  • the liquid composition of the product subject to this patent application consists of silymarin phytosome in a percentage ranging from 0.203 to 0.30%, sodium salt of pyrroloquinoline quinone in a percentage ranging from 0.03% to 0.10%, myricetin in a percentage ranging from 0.50% to 0.80%, H2O in a percentage ranging from 60% to 75%, and components commonly known in the relevant field for formulating liquid food products in a percentage ranging from 25% to 40%.
  • the commonly known components in the relevant field for formulating liquid food products can include, by way of example and not limitation, fructose, citric acid, flavors, potassium sorbate, and sodium benzoate.
  • the solid composition of the product subject to this patent application consists of silymarin phytosome in a percentage ranging from 10% to 15%, sodium salt of pyrroloquinoline quinone in a percentage ranging from 2% to 4%, myricetin in a percentage ranging from 30% to 40%, and components known for formulating solid food products in a percentage ranging from 41% to 58%.
  • the known components for formulating solid food products can consist of N-Acetylcysteine, flavors, glyceryl monobehenate, silica, sucralose.
  • CBC complete blood count
  • AST ALT
  • GGT total and fractionated bilirubin
  • the alcoholic beverage administered consisted of a quantity of 150 ml of Cabernet red wine (alcohol content: 12.5-13%; alcohol content per serving: 14.81 - 15.40 g, corresponding to the average drink size as indicated by Kerr et al.) throughout the duration of the experiment and for ail subjects.
  • the placebo or the product subject to this patent application was consumed immediately after drinking the glass of wine. Subjects then continued consumption for a week by drinking, in similar manners, one glass (150 ml; at lunch and one at dinner (total of 300 ml/day, approximately 30g of alcohol/day) of the provided red wine, while taking the prescribed placebo or the product subject to this patent application (according to the randomization group) .
  • Table 1 shows that the blood alcohol concentration at day 1, 120 minutes after intake, is over 33% higher in those who took the placebo compared to those who took the product subis i s p a t e n t app 1 i cat
  • the histogram in Table 2 displays the value of ethyl glucuronide (EtG) , a metabolic product of ethanol formed in the body through conjugation of ethanol with glucuronic acid, measured on day 1 at 120 minutes after intake.
  • EtG ethyl glucuronide
  • the redox state namely the analysis of amino thiols, was quantified from RBC (Red Blood Cells) using HPLC.
  • the histogram shows an increasing trend in uric acid at 7 days (+35%) after intake of the product subject to this patent application. This data strengthens the statistical significance of Total Antioxidant Capacity (TAG) , supporting the concept of the antioxidant power of the product under this patent application. (Table 12B) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition alimentaire capable de supprimer les effets négatifs du taux d'alcool dans le sang, d'abaisser le taux d'alcool dans le sang en stimulant son métabolisme.
EP23841545.9A 2022-12-13 2023-12-11 Produit alimentaire destiné à être utilisé dans la prévention et le traitement de xylostomiases induites par l'alcool Pending EP4633390A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT202200025452 2022-12-13
PCT/IT2023/050275 WO2024127440A1 (fr) 2022-12-13 2023-12-11 Produit alimentaire destiné à être utilisé dans la prévention et le traitement de xylostomiases induites par l'alcool

Publications (1)

Publication Number Publication Date
EP4633390A1 true EP4633390A1 (fr) 2025-10-22

Family

ID=85381066

Family Applications (1)

Application Number Title Priority Date Filing Date
EP23841545.9A Pending EP4633390A1 (fr) 2022-12-13 2023-12-11 Produit alimentaire destiné à être utilisé dans la prévention et le traitement de xylostomiases induites par l'alcool

Country Status (2)

Country Link
EP (1) EP4633390A1 (fr)
WO (1) WO2024127440A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120168473A (zh) * 2025-05-21 2025-06-20 深圳先进技术研究院 一种治疗酒精依赖的药物组合物及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190298684A1 (en) * 2018-03-27 2019-10-03 So Young Life Sciences Corporation Compositions For Reducing Negative Effects Of Alcohol Consumption
US11096904B2 (en) * 2018-05-11 2021-08-24 Linda J. Kaplan Methods and nutraceutical compositions for the prevention and/or mitigation of veisalgia
CN112274547B (zh) * 2020-11-12 2024-12-27 南京北极光生物科技有限公司 一种含有水飞蓟提取物和1,6二磷酸果糖的组合物及其在护肝、醒酒、抗疲劳中的应用
US11458155B1 (en) * 2021-11-16 2022-10-04 Fulgent Life Inc. Active ingredient complexes, compositions and methods for hangover relief and to ameliorate alcohol-induced liver damage
CN114796197A (zh) * 2022-03-16 2022-07-29 大方萃谷生物科技有限公司 一种解酒护肝组合物及其制剂
CN114747768A (zh) * 2022-05-19 2022-07-15 大闽食品（漳州）有限公司 一种包含pqq的保肝组合物

Also Published As

Publication number Publication date
WO2024127440A1 (fr) 2024-06-20

Similar Documents

Publication Publication Date Title
EP3240555B1 (fr) Compositions multi-compléments
Ikematsu et al. Safety assessment of coenzyme Q10 (Kaneka Q10) in healthy subjects: a double-blind, randomized, placebo-controlled trial
AU2005211936B2 (en) Alcohol metabolism moderating composition
CN106072659A (zh) 多元机体抗氧化营养素组合物及其应用
Hosseinzadeh-Attar et al. Reduction in asymmetric dimethylarginine plasma levels by coenzyme Q10 supplementation in patients with type 2 diabetes mellitus
Pereira Braga et al. Influence of treatment with quercetin on lipid parameters and oxidative stress of pregnant diabetic rats
Arshad et al. Lipid stability and antioxidant profile of microsomal fraction of broiler meat enriched with α-lipoic acid and α-tocopherol acetate
Armanfar et al. Effect of coenzyme Q10 supplementation on exercise-induced response of oxidative stress and muscle damage indicators in male runners
EP4633390A1 (fr) Produit alimentaire destiné à être utilisé dans la prévention et le traitement de xylostomiases induites par l'alcool
Case et al. Low‐Dose Aronia melanocarpa Concentrate Attenuates Paraquat‐Induced Neurotoxicity
Olabiyi et al. Palm oil and ground nut oil supplementation effects on blood glucose and antioxidant status in alloxan-induced diabetic rats
Cho et al. Effect of Evodiae fructus extracts on gene expressions related with alcohol metabolism and antioxidation in ethanol-loaded mice
Lei et al. Effect of squid ink melanin‐Fe on iron deficiency anemia remission
US11090274B2 (en) Formulation and method for supporting retinal health thereby reducing the risk of age-related macular degeneration (AMD)
CN114272273A (zh) 一种含有nmn的抗氧化组合物及其制备方法
Bhagat et al. Attenuation of serum ferritin and iron burden by intake of antioxidants in beta thalassemia major
Elemo et al. Underutilized legumes, Cajanus cajan and Glycine max may bring about antisickling effect in sickle cell disease by modulation of redox homeostasis in sickled erythrocytes and alteration of its functional chemistry
EP3930727B1 (fr) Composition antioxydante comprenant de la polydatine et de l'acétylcystéine
Esan et al. The Effects of okra (Abelmoschus esculentus (L) M oench) fruit extracts on diabetes markers in streptozotocin-induced diabetic rats. Arch
Tonin et al. Vitamins, antioxidants, and type 2 diabetes
Hamadi et al. Potential Effect of Spirulina Extracts on Serum Iron Reduction: Possible Application in Cancer Treatment
Nenseth et al. A Nutraceutical Formula Is Effective in Raising the Circulating Vitamin and Mineral Levels in Healthy Subjects: A Randomized Trial
Liao et al. Ameliorating effect of Chinese jujube polyphenol on blood glucose oxidative stress in type 2 diabetic rats
IT202200005136U1 (it) Prodotto ad uso alimentare per uso nella prevenzione e trattamento dei postumi da ubriachezza
Mathis et al. Endogenous and exogenous protection from surgically induced reactive oxygen and nitrogen species

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20250709

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR